

SZAFERMAN LAKIND

Szaferman, Lakind, Blumstein & Blader, P.C.
Attorneys at Law

101 Grovers Mill Road, Suite 200
Lawrenceville, NJ 08648
P: 609.275.0400
F: 609.275.4511
www.szaferman.com

Arnold C. Lakind
Barry D. Szaferman
Jeffrey P. Blumstein
Steven Blader
Brian G. Paul+
Craig J. Hubert++
Michael R. Paglione*
Lionel J. Frank**
Jeffrey K. Epstein+
Stuart A. Tucker
Scott P. Borsack***
Daniel S. Sweetser*
Robert E. Lytle
Janine G. Bauer***
Daniel J. Graziano Jr.
Nathan M. Edelstein**
Bruce M. Sattin***
Gregg E. Jaclin**
Robert P. Panzer
Benjamin T. Branche*
Robert G. Stevens Jr.**

Of Counsel
Stephen Skillman
Linda R. Feinberg
Anthony J. Parrillo
Paul T. Koenig, Jr.
Robert A. Gladstone
Janine Danks Fox*
E. Elizabeth Sweetser
Keith L. Hovey

Michael D. Brottman**
Lindsey Moskowitz Medvin**
Mark A. Fisher
Robert L. Lakind***
Thomas J. Manzo**
Carley Ward**
Melissa A. Chimbangu
Kathleen O'Brien
Steven A. Lipstein**
Yarona L. Yieh#
Brian A. Heyesey
Mengyi "Jason" Ye
John O'Leary***
Christopher S. Myles
Christopher S. Kwelty

+Certified Matrimonial Attorney
++Certified Civil and Criminal Trial Attorney
*NJ & PA Bars
**NJ & NY Bars
***NJ, NY & PA Bars
#NY Bar

April 22, 2016

OTC Markets Group Inc.
304 Hudson Street, Second Floor
New York, NY 10013

**Re: Adequate Current Information regarding
Axxess Pharma, Inc.**

OTC Markets Group:

We have been requested by Axxess Pharma, Inc. (the "Company") to render an opinion as to whether there is adequate current information available on the OTC Disclosure and News Service regarding the Company pursuant to Rule 144(c)(2) under the Securities Act of 1933, as amended (the "Securities Act") and Rule 15c2-11 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

We are authorized to practice law in the State of New York, the State of New Jersey, and the Commonwealth of Pennsylvania. Our law firm is permitted to practice before the Securities and Exchange Commission (the "SEC") and has not been prohibited from practice thereunder.

We have relied on information obtained from public officials, officers of the Company and other sources, where such sources are believed to be reliable, and examined such corporate records and other documents and such questions of law as we consider necessary or appropriate for purpose of rendering this opinion.

We have also reviewed the following documents in connection with the preparation of this letter (the "Materials"):

- Annual Report dated April 21, 2016 and posted through the OTC Disclosure & New Service on April 21, 2016 (the "Annual Report");
- a copy of the Articles of Incorporation of the Company filed with the Secretary of State of Nevada on August 13, 2012;
- a copy of the Bylaws of the Company adopted on December 6, 2012;

- a copy of the Good Standing Certificate from the Secretary of State of the State of Nevada as of April 20, 2016;
- a copy of the certified list of common stockholders of the Company prepared as of April 20, 2016, issued by Corporate Stock Transfer, Inc. the transfer agent attesting to the number of shares of outstanding common stock of the Company (the "Certified List");
- the resolution of the Board of Directors of the Company dated April 21, 2016 upon unanimous written consent relating to, without limitation, approving the Annual Report and authorizing the posting of such Annual Report through the OTC Disclosure & New Service; and
- the certificate of the officer of the Company dated April 21, 2016 (the "Officer's Certificate").

We have assumed that (i) all information contained in all documents reviewed by us is true and correct, (ii) all signatures on these documents reviewed by this firm are genuine, (iii) all documents submitted to this firm as originals are true and complete, (iv) all documents submitted to this firm as copies are true and complete copies of the originals thereof, and (v) each natural person signing any document submitted to this firm had the legal capacity to do so.

The Company's financial statements contained in the Annual Report were prepared by Carrolton Partners, LLC, with an address at 77 E. Main Street, Suite 406, Westminster, MD 21157. Its phone number is (410) 790-8627. Carrolton Partners, LLC regularly provides accounting and consulting services to publically traded companies in the United States. The Company's financial statements have not been audited.

The Company's transfer agent is Corporate Stock Transfer, Inc., with an address at 3200 Cherry Creek Drive South, Suite 430, Denver, CO 80209. Corporate Stock Transfer, Inc. is registered with the Securities and Exchange Commission. We confirmed that there are 20,106,627 and 20,000,000 shares of common stock and preferred stock of the Company issued and outstanding, respectively, as set forth in the Annual Report by reviewing the Certified List. We also confirmed the number of outstanding shares of preferred stock set for the in the Annual Report upon reviewing the Officer's Certificate.

We have reviewed the website maintained by otcmarkets.com for the purpose of determining whether the Annual Report was posted thereon.¹ As of the date hereof, the Annual Report is posted on the website and is available for public inspection and review.

We have (i) personally met with the management of the Company and a majority of the directors of the Company, (ii) reviewed the Annual Report, published by the Company through the OTC Disclosure and News Service, and (iii) discussed such information with the management and a majority of the directors of the Company.

To the best of our knowledge², after inquiry of management and the directors of the Company, no one of the Company, the Company's officer, director or 5% holder, or our law firm are currently under

¹ <http://www.otcmarkets.com/stock/AXXE/filings>

² Whenever a statement herein is qualified by "to our knowledge" or similar phrase, it means that, during the course of our representation of the Company for the purposes of this opinion letter, information actually known by those lawyers who participated in the preparation of the letter or worked in any capacity on the transactions contemplated after consultation with such other attorneys in our firm who have rendered substantive advice to Company and a review of documents in our possession as they deemed appropriate. As to certain questions of fact material to this

investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

We have been asked to provide several opinions herein. First, we have been asked to opine that, as of the date hereof, the materials (i) constitute “adequate current public information”³ as detailed in Rule 15(c)(2)(11)(a)(5)(i)-(xiv) and (xvi)⁴ concerning the Company and its common stock, and that such public information is “available” within the meaning of Rule 144(c)(2) under the Securities Act.⁵ After a review of the materials, it is our opinion that the materials constitutes ‘adequate public information’ which is “available within the meaning of Rule 144(c)(2) and Rule 15(c)(2)(11)(a)(5).

Further, we have been asked opine that the materials contain all the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Company’s common stock in accordance with Rule 15c2-11 under the Exchange Act.⁶ After reviewing the Annual Report and the requirements of Rule 15c2-11, it is our opinion that the Annual Report contains all the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Company’s common stock under Rule 15c2-11 under the Exchange Act.

Further, we have been asked whether in our opinion the contents of the Annual Report comply with the OTC Markets Group’s OTC Pink Basic Disclosure Guidelines, which are located on the internet at www.otcm Markets.com. We have compared the requirements as published by the OTC Markets Group to the contents of the Annual Report and conclude that the Annual Report satisfies the various disclosure requirements set forth in the published guidelines.

OTC Markets Group, is entitled to rely upon this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, and is permitted to publish the letter in the OTC Disclosure and News Service for viewing by the public and regulators. This letter is being delivered solely for the benefit of OTC Markets Group and may not be relied upon by any other person, quoted by or filed with any governmental authority or other regulatory agency, or otherwise circulated or utilized for any other purpose without our prior written consent in each such case.

opinion, we have relied upon statements or certificates from the Company or person(s) acting on behalf of the Company.

³ Rule 144(c)(2) states under “current public information” that adequate current public information with respect to the issuer of the securities must be available. Such information will be deemed to be available for non-reporting companies if the items in Rule 15(c)(2)(11)(a)(5)(i) to (xiv) and (a)(5)(xvi) are provided.

⁴ Rule 15(c)(2)(11)(5) outlines the information that is required by a broker-dealer. The items listed under Rule 15(c)(2)(11) include: (i) issuer name, (ii) address of principal executive offices, (iii) state of incorporation, (iv) exact title and class of security, (v) par value of security, (vi) number of securities outstanding as of the most recent fiscal year end, (vii) name and address of transfer agent, (viii) nature of issuer’s business (ix) nature of products or services offered, (x) nature of issuer’s facilities, (xi) names of CEO and board members, (xii) the issuer’s most recent balance sheet and profit and loss and retained earnings statements, (xiii) similar financial information for the past two fiscal years, (xiv) whether the issuer has a broker or dealer who is affiliated directly or indirectly with the issuer and (xvi) the equity securities held by the officers and directors of the issuer and any beneficial owners of more than 10 percent of the outstanding equity securities of the issuer.

⁵ *Supra*, note 2.

⁶ *Supra*, note 3.

The opinions expressed in this letter are made only as of the date hereof. We assume no obligation to update or supplement this letter to reflect facts or circumstances which may hereafter come to our attention with respect to this letter and the statements expressed above, including any changes in applicable law which may hereafter occur.

Regards,

SZAFERMAN, LAKIND, BLUMSTEIN & BLADER, PC

By: _____

Gregg E. Jaclin
For the Firm